The TAVR benchmarks you've been waiting for

Six takeaways from 2014 TAVR data

By Megan Tooley and Brian Contos

It’s been over four years since TAVR was first approved by the FDA. Yet the excitement surrounding this game-changing procedure has not waned, particularly as evolving next-gen devices continue to hit the market, and indications look poised to expand to intermediate-risk patients in the not-too-distant future—with low-risk patients perhaps not far behind.

So how have the TAVR market and practice patterns changed in this time? To give some insight into programs evaluating TAVR entry or looking to benchmark their existing program, we’ve updated our TAVR benchmarks with the latest Medicare Provider Analysis and Review (MEDPAR) data set for fiscal year (FY) 2014. This includes all Medicare TAVR cases performed between October 1, 2013, and September 31, 2014.

Read on for our key takeaways on TAVR performance in FY 2014.

Log in to access this.

Full access to this content is reserved for Cardiovascular Roundtable members.
Log in or learn how membership works.